Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Beate, Mayrbäurl"'
Autor:
Beate Mayrbäurl, Teresa Magnes, Johannes Andel, Simon Peter Gampenrieder, Florian Huemer, Thorsten Füreder, Lukas Weiss, Sandro M. Wagner, M. Kopp, Gabriel Rinnerthaler, Daniel Lenger, Alexander Egle, Thomas Melchardt, Richard Greil
Publikováno v:
Wiener klinische Wochenschrift. 133:1131-1136
Summary Background The addition of cisplatin or cetuximab to radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) has significantly improved the outcome. While the superiority of cisplatin over cetuximab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8033ed9b33f1aeeb8ec394e50c3e33ae
https://doi.org/10.1007/s00508-021-01939-3
https://doi.org/10.1007/s00508-021-01939-3
Autor:
Michael Fiegl, Wolfgang Hilbe, Hellmut Samonigg, David Fuchs, H. Stöger, Maria Johanna Schandl, Josef Thaler, Heinz Ludwig, Marija Balic, Peter Krippl, Andreas L. Petzer, Beate Mayrbäurl, Reinhard Stauder, Richard Greil, Sylvia Gusel, Brigitte Mlineritsch, Florian Eisner, Wolfgang Stangl, Ansgar Weltermann, Karin Hegenbarth
Publikováno v:
memo - Magazine of European Medical Oncology. 12:290-296
Summary The purpose of this observational study was to determine the prevalence of comorbid conditions in cancer patients with solid tumours selected for specific treatment at 12 divisions of medical oncology in Austria. Data from 1137 patients were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c1ab5f3c3f82006caba1145ccfe8197
https://doi.org/10.1007/s12254-019-00542-7
https://doi.org/10.1007/s12254-019-00542-7
Autor:
Maximilian Hartl, Richard Greil, Alexander de Vries, Martin Burian, Michael A. Fridrik, Gabriela Altorjai, Felix Keil, Regina Riedl, Andrea Berghold, Martin Pecherstorfer, Thorsten Fuereder, Beate Mayrbäurl
Publikováno v:
Journal of Clinical Oncology. 37:6027-6027
6027 Background: Induction chemotherapy (ICT) with Cisplatin (P), 5-FU (F) and Taxanes (T) is a therapeutical option in patients suffering from locally advanced or unresectable stage III or IV squamous cell carcinoma of the head and neck (SCCHN). The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::35add437d8145de48b8cff1ad41f07d1
https://doi.org/10.1200/jco.2019.37.15_suppl.6027
https://doi.org/10.1200/jco.2019.37.15_suppl.6027
Autor:
Sonja Burgstaller, Johannes M. Giesinger, Lisa M. Wintner, Josef Thaler, Th. Himmelfreundpointner, Beate Mayrbäurl, Bernhard Holzner
Publikováno v:
Supportive Care in Cancer. 20:2399-2405
The aim of this study was to investigate quality of life (QOL) differences between patients receiving first, second, or third-line palliative chemotherapy (CT).Furthermore, QOL was also compared to a sex- and age-matched sample of healthy controls. P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee14f88d8cdef11549e4b98b5d0dec0f
https://doi.org/10.1007/s00520-011-1355-x
https://doi.org/10.1007/s00520-011-1355-x
Autor:
Josef Thaler, Sonja Burgstaller, Beate Mayrbäurl, Johannes M. Giesinger, Gudrun Piringer, Bernhard Holzner
Publikováno v:
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 24(2)
Palliative chemotherapy in patients with nonresectable advanced colorectal carcinoma is performed to prolong survival, alleviate tumor-associated symptoms, and maintain or improve health-related quality of life (HRQOL). In this prospective single-cen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcd5c311d2b02254838ae8d0ae8093d7
https://pubmed.ncbi.nlm.nih.gov/26123602
https://pubmed.ncbi.nlm.nih.gov/26123602
Autor:
Rainer Pöhnl, Michael Pötscher, Thomas Kühr, Sabine Hojas, Beate Mayrbäurl, Daniela Zauner, Josef Thaler, Heinz Gisslinger, Michael A. Fridrik, Heinz Ludwig, Sonja Burgstaller, Ernst Schlögl
Publikováno v:
Wiener klinische Wochenschrift. 125(7-8)
Current literature provides conflicting evidence regarding the efficacy of lenalidomide in patients with myelofibrosis (MF). The aim of this work was to evaluate the efficacy of lenalidomide in patients with MF treated within a named patient program
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f217c373b9dc378a0d81daeb13357bcb
https://pubmed.ncbi.nlm.nih.gov/23536018
https://pubmed.ncbi.nlm.nih.gov/23536018
Autor:
Ewald, Wöll, Richard, Greil, Wolfgang, Eisterer, Oliver, Bechter, Michael A, Fridrik, Birgit, Grünberger, August, Zabernigg, Beate, Mayrbäurl, Gudrun, Russ, Margit, Dlaska, Peter, Obrist, Josef, Thaler
Publikováno v:
Anticancer research. 31(12)
Patients suffering from advanced gastric cancer still have a poor prognosis and treatment options are limited. In our previous phase II trial (AGMT-Gastric-1), we showed that the combination of oxaliplatin and irinotecan was well tolerated and effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::174fe775bc735dbb3119df116713a749
https://pubmed.ncbi.nlm.nih.gov/22199312
https://pubmed.ncbi.nlm.nih.gov/22199312
Autor:
Beate, Mayrbäurl, Josef, Thaler
Publikováno v:
Acta medica Austriaca. 31(2)
The increase in cancer incidence with increasing age is becoming more obvious and more important as the average age of population increases. Currently over 50% of all cancers occur in people who are 65 and older. The clinical behaviour of common mali
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1d90371e271fb664f148ebf42968504e
https://pubmed.ncbi.nlm.nih.gov/15359981
https://pubmed.ncbi.nlm.nih.gov/15359981
Autor:
T. Sliwa, Beate Mayrbäurl, R. Schaberl-Moser, G. Resch, Richard Greil, Josef Thaler, G. Kopetzky, P. Kier, Werner Scheithauer, Thomas Nösslinger
Publikováno v:
Annals of Oncology. 22:486-487
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cac76a5e6716e3836fd4e28684d7b4e
https://doi.org/10.1093/annonc/mdq744
https://doi.org/10.1093/annonc/mdq744
Autor:
Richard Greil, Birgit Grünberger, A. Zabernigg, Beate Mayrbäurl, Ewald Woell, Josef Thaler, G. Russ, Wolfgang Eisterer, Michael A. Fridrik
Publikováno v:
Journal of Clinical Oncology. 27:4538-4538
4538 Background: Patients (pts.) suffering from advanced gastric cancer have still a poor prognosis and treatment options are limited. In our previous phase II trial (AGMT-Gastric-1) we could show that the combination of oxaliplatin and irinotecan wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0792998638192e152164af44e60fc1aa
https://doi.org/10.1200/jco.2009.27.15_suppl.4538
https://doi.org/10.1200/jco.2009.27.15_suppl.4538